Certain regulatory issues surround P4P programs

Article

As CMS has begun to promote its quality agenda through pay-for-performance (P4P) initiatives, private payers should consider certain regulatory issues in establishing such programs.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
Site Logo

Product Profile: MONJUVI (tafasitamab-cxix injection, for intravenous use)

August 24th 2025
Article

Read More

Conversations with Perry and Friends: Jon Bloom, M.D.

Conversations with Perry and Friends: Jon Bloom, M.D.

Perry Cohen, Pharm.D.
August 24th 2025
Podcast

Listen

A Conversation With Alexa D’Angelo, Ph.D., M.P.H., Recent Doctoral Graduate from the CUNY School of Public Health and Health Policy

A Conversation With Alexa D’Angelo, Ph.D., M.P.H., Recent Doctoral Graduate from the CUNY School of Public Health and Health Policy

Logan Lutton
August 24th 2025
Article

Read More

Conversations with Perry and Friends: Saar Mahna, J.D., MBA

Conversations with Perry and Friends: Saar Mahna, J.D., MBA

Perry Cohen, Pharm.D.
August 24th 2025
Podcast

Listen

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

Logan Lutton
August 24th 2025
Article

Read More

ryanking999-stock.adobe.com

FDA Set Review Date for Imcivree for Rare Form of Obesity

Denise Myshko
August 24th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.